In the group with fewer than two prior hospitalizations, vericiguat therapy was associated with favorable cardiac reverse remodeling, evidenced by a significant reduction in plasma BNP levels and a significant improvement in LVEF over 6 months despite other heart failure medications remaining unchanged. The gene discussed is NPPB; the disease is heart failure.